title: Good clinical and cost outcomes using dexrazoxane to treat accidental epirubicin extravasation.
abstract: A 75-year-old man diagnosed with lower esophageal adenocarcinoma suffered from epirubicin extravasation during the second cycle of neoadjuvant chemotherapy with epirubicin and oxaliplatin. A full recovery was achieved after treatment with dexrazoxane (Cardioxane® ). This is the first time in our hospital that extravasation of an anthracycline has been treated with dexrazoxane. We used Cardioxane® , approved for the prevention of anthracycline-induced cardiotoxicity, while Savene® is indicated for the treatment of anthracycline extravasation. The treatment was effective, and the selection of Cardioxane® (seven-fold cheaper than Savene® ) yielded a cost saving. Consequently, Cardioxane® has been included in our guidelines for anthracycline extravasation.
authors.affiliation: Department of Pharmacy, Virgen de las Nieves University Hospital, Avenida de las Fuerzas Armadas, 2. Granada -180 12, Spain. patrippg_chl@yahoo.es
authors.forename: Patricia Araque
authors.initials: PA
authors.lastname: Arroyo
authors.forename: Ruth Ubago
authors.initials: RU
authors.lastname: Perez
authors.forename: Maria Amalia Fernandez
authors.initials: MA
authors.lastname: Feijoo
authors.forename: Miguel Angel Calleja
authors.initials: MA
authors.lastname: Hernandez
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D003362:Cost-Benefit Analysis; D015251:Epirubicin / Q000009:adverse effects*; D005119:Extravasation of Diagnostic and Therapeutic Materials; D006801:Humans; D008297:Male; D011929:Razoxane / Q000191:economics / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D015251:Epirubicin; D011929:Razoxane